Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others.

The report provides information and insights into Boehringer Ingelheim' tech activities, including:

• Insights of its digital transformation strategies and innovation programs.
• Overview of technology initiatives covering partnerships, product launches, investments, and acquisitions.
• Insights on each technology initiative including technology theme, objective, and benefits.
• Details of estimated ICT budgets and major ICT contracts.

Scope

• The report provides insights into company’s tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.

Reasons to Buy

• Gain insights into Boehringer Ingelheim' tech operations.
• Gain insights into its tech strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into various product launches, partnerships, investments, and acquisitions.